Global Drug Development Market Thematic Research Report 2021: Immuno-oncology, Precision and Personalized, Regenerative, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, and AI – ResearchAndMarkets.com

Global Drug Development Market Thematic Research Report 2021: Immuno-oncology, Precision and Personalized, Regenerative, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, and AI – ResearchAndMarkets.com




Global Drug Development Market Thematic Research Report 2021: Immuno-oncology, Precision and Personalized, Regenerative, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, and AI – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Drug Development Sector Scorecard – Thematic Research” report has been added to ResearchAndMarkets.com’s offering.

The pharmaceutical industry is under increasing pressures with rising R&D costs, patent expiries, greater competition, and pricing challenges all eroding profit margins. Companies must invest in the right areas of drug development to maximize profitability and minimize risk.

Some of the most profitable or rapidly growing areas include immuno-oncology, regenerative medicine, precision and personalized medicine, biosimilars, genomics, and nanotechnology.

Companies can also forge strategic partnerships in R&D leading to risk diversification, new product development, shortened drug development timelines, and reduced costs. The industry is also investing in new technologies, such as artificial intelligence (AI) to improve drug development.

Scope

  • The publisher’s Drug Development Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the drug development sector over the next two to four years.
  • These themes are Immuno-oncology, Precision and Personalized Medicine, Regenerative Medicine, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, Strategic Alliances, and Artificial Intelligence.
  • The scorecard includes 55 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • The methodology contains detailed information on what data sources were used to generate the thematic scores for each company.

Reasons to Buy

  • Identify the key drug development themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Key Topics Covered:

  • Executive Summary
  • Introduction
  • Pharma Theme Map
  • Drug Development Scorecard
  • Company Screen
  • Thematic Screen
  • Valuation Screen
  • Thematic Research Methodology
  • How Pharma Scores Are Generated

Companies Mentioned

  • Takeda Pharmaceutical Co Ltd
  • Merck & Co Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Johnson & Johnson
  • Boehringer Ingelheim
  • Parexel International Corp
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • Eli Lilly and Co
  • IQVIA Holdings Inc
  • AbbVie Inc
  • Merck KGaA
  • Novo Nordisk AS
  • Catalent Inc
  • Gilead Sciences Inc
  • Thermo Fisher Scientific Inc
  • Astellas
  • Biogen Inc
  • Cipla Ltd
  • Lonza Group Ltd
  • Amgen Inc
  • Daiichi Sankyo Co Ltd
  • Vertex Pharmaceuticals Inc
  • WuXi AppTec Co Ltd
  • Charles River Laboratories International Inc
  • CSL Ltd
  • Reliance Life Sciences Pvt Ltd
  • Sanofi
  • Innovent Biologics Inc
  • Otsuka
  • Teva Pharmaceutical Industries Ltd
  • UCB
  • Dr. Reddy’s Laboratories Ltd
  • Regeneron Pharmaceuticals Inc
  • Samsung Bioepis Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Alexion Pharmaceuticals Inc
  • Biocad
  • Cadila Pharmaceuticals Ltd
  • Celltrion Inc
  • Coherus BioSciences Inc
  • CSPC Pharmaceutical Group Ltd
  • Generium
  • Intas Pharmaceuticals Ltd
  • Lupin Ltd
  • Perrigo Co Plc
  • Pharmaceutical Product Development LLC
  • Seagen Inc
  • Shanghai Henlius Biotech Inc
  • Viatris Inc
  • Zydus Cadila

For more information about this report visit https://www.researchandmarkets.com/r/cktiqu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900